Salesforce, Inc. CRM
Composite 52/100; the shares have moved about 56% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Balance-sheet strength ranks 28/100 — a moderate mark against it.
Growth ranks 64/100 — a moderate point in its favour. Valuation ranks 62/100 — a slight point in its favour. Momentum ranks 57/100 — a slight point in its favour.
Balance-sheet strength ranks 28/100 — a moderate mark against it. Income ranks 46/100 — a slight mark against it.
What the company does Salesforce provides cloud-based CRM and AI-powered enterprise software, integrating customer data, sales, service, and agentic workflows via platforms like Agentforce and Slack.
Key financials Revenue grew 10.8% with net margins at 22.0% and operating margins at 21.4%. ROE is 19.4% and EPS growth is 118.9%. Debt/Equity is 1.10 with a net debt/EBITDA of 2.40; free cash flow yield is 8.3%.
Stock health Momentum is strong: 3m +28.85%, 6m +32.33%, but down -3.60% from the 52-week high. RSI(14) is 81.30, indicating overbought conditions. Sideravia scores Quality 68.0 and Growth 65.5, but Strength 34.2 and Income 39.8 are weak.
Price vs fair value The stock trades at a discount of 3.20% versus the analyst mean target of 266.48. - Recent Q2 results and raised guidance support valuation (Is Salesforce (CRM) Cheap On Strong Q2 Results And Higher Guidance?) - AI partnerships and integrations with Microsoft and others are cited as growth drivers (Salesforce: Its Biggest AI Threat Just Became Its Partner; NOW Broadens Aramco AI Footprint as CRM & MSFT Expand AI Ambitions) - Analysts highlight an enterprise software rebound tailwind (Jim Cramer Breaks Down the Enterprise Software Rebound for Salesforce (CRM) and Veeva (VEEV))
Looking forward Forward P/E of 16.22 and PEG of 0.35 suggest potential margin expansion and AI-led efficiency gains, though high RSI and valuation percentile 52.6/100 indicate limited near-term upside without further catalysts.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.